[go: up one dir, main page]

MX2018004831A - Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. - Google Patents

Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.

Info

Publication number
MX2018004831A
MX2018004831A MX2018004831A MX2018004831A MX2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A MX 2018004831 A MX2018004831 A MX 2018004831A
Authority
MX
Mexico
Prior art keywords
methods
protein
fucosilated
afucosilated
forms
Prior art date
Application number
MX2018004831A
Other languages
English (en)
Inventor
B Lowe John
Misaghi Shahram
R Snedecor Bradley
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2018004831A publication Critical patent/MX2018004831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud hace referencia a métodos para producir una proteína en forma fucosilada y afucosilada con una relación predeterminada.
MX2018004831A 2015-11-02 2016-11-01 Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. MX2018004831A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249828P 2015-11-02 2015-11-02
US201662338280P 2016-05-18 2016-05-18
PCT/US2016/059922 WO2017079165A1 (en) 2015-11-02 2016-11-01 Methods of making fucosylated and afucosylated forms of a protein

Publications (1)

Publication Number Publication Date
MX2018004831A true MX2018004831A (es) 2018-08-01

Family

ID=57326491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004831A MX2018004831A (es) 2015-11-02 2016-11-01 Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.

Country Status (14)

Country Link
US (3) US10975168B2 (es)
EP (2) EP3371206B1 (es)
JP (1) JP6983772B2 (es)
KR (2) KR20250051156A (es)
CN (2) CN108431026B (es)
AU (2) AU2016350732A1 (es)
BR (1) BR112018007356A2 (es)
CA (1) CA2999047A1 (es)
ES (1) ES2875274T3 (es)
IL (1) IL258161B2 (es)
MX (1) MX2018004831A (es)
PL (1) PL3371206T3 (es)
SG (2) SG11201802773RA (es)
WO (1) WO2017079165A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371206B1 (en) 2015-11-02 2021-04-14 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
MX2018008447A (es) * 2016-01-06 2019-05-30 Oncobiologics Inc Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
CN113166728A (zh) * 2018-08-29 2021-07-23 联合生物制药股份有限公司 去岩藻醣基化抗体及其制造
WO2020055900A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
FI3941946T3 (fi) 2019-03-20 2025-03-28 Univ California Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
JP2023530208A (ja) 2019-05-06 2023-07-14 アムジェン インコーポレイテッド 抗体エフェクター機能の調節
WO2021062372A1 (en) * 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
WO2021072244A1 (en) * 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
MX2022015948A (es) * 2020-07-02 2023-04-05 Gigagen Inc Proteínas de unión anti-ctla-4 y métodos de uso de estas.
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CA3227687A1 (en) * 2021-08-06 2023-02-09 Marc Andrew GILLIG Process for producing personalized cancer immunotherapy
KR102890992B1 (ko) * 2023-01-26 2025-12-02 팔라디바이오텍 주식회사 물질의 세포막 파괴 활성을 확인하는데 사용하기 위한 조성물, 및 그의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
EP1117815A1 (en) 1998-09-29 2001-07-25 Pioneer Hi-Bred International Inc. Mar/sar elements flanking rsyn7-driven construct
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
AU2002216443A1 (en) 2000-12-15 2002-06-24 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fointerferon beta
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
AU2006255085A1 (en) * 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
AU2006270718B2 (en) * 2005-07-22 2011-07-21 Kyowa Kirin Co., Ltd. Genetically modified antibody composition
BRPI0715580A2 (pt) * 2006-10-12 2014-06-10 Genentech Inc ''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO''
KR101641526B1 (ko) * 2009-06-02 2016-07-21 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
AU2010256455A1 (en) * 2009-06-05 2012-01-19 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
EP2683821B1 (en) * 2011-03-06 2018-07-25 Merck Serono SA Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
EP3036320B2 (en) * 2013-08-19 2024-04-03 Biogen MA Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
WO2016075662A2 (en) * 2014-11-15 2016-05-19 Zumutor Biologics, Inc. Dna-binding domain, non-fucosylated and partially fucosylated proteins, and methods thereof
JP6587696B2 (ja) * 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
EP3371206B1 (en) 2015-11-02 2021-04-14 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein

Also Published As

Publication number Publication date
KR102793554B1 (ko) 2025-04-14
SG11201802773RA (en) 2018-05-30
AU2016350732A1 (en) 2018-04-05
KR20250051156A (ko) 2025-04-16
US20240158536A1 (en) 2024-05-16
EP3925970A1 (en) 2021-12-22
PL3371206T3 (pl) 2021-09-27
CA2999047A1 (en) 2017-05-11
US20210214462A1 (en) 2021-07-15
US11802165B2 (en) 2023-10-31
BR112018007356A2 (pt) 2018-10-23
US12391769B2 (en) 2025-08-19
WO2017079165A1 (en) 2017-05-11
CN116731147A (zh) 2023-09-12
EP3371206B1 (en) 2021-04-14
JP6983772B2 (ja) 2021-12-17
CN108431026B (zh) 2023-02-17
SG10202103875WA (en) 2021-06-29
IL258161A (en) 2018-05-31
EP3371206A1 (en) 2018-09-12
IL258161B1 (en) 2023-04-01
KR20180068967A (ko) 2018-06-22
JP2019505164A (ja) 2019-02-28
IL258161B2 (en) 2023-08-01
US20180251572A1 (en) 2018-09-06
CN108431026A (zh) 2018-08-21
ES2875274T3 (es) 2021-11-10
US10975168B2 (en) 2021-04-13
AU2022202460A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2018004831A (es) Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.
IL271011A (en) Triple combination antibody therapies
CL2019002824A1 (es) Anticuerpos anti-lag3.
EP3576896A4 (en) ADDITIVE MANUFACTURING IN THE PRESENCE OF NANOFUNCTIONALIZED PRECURSORS
CA167019S (en) Thermometer
CR20160450A (es) Anticuerpos multiespecificos
EP3152616A4 (en) Efficient, dynamic, high contrast lensing with applications to imaging, illumination and projection
EP3634324C0 (en) OSTOMY BARRIER COMPRISING DERMATOLOGICAL SUBSTANCES
EP3523540C0 (en) LUBRICATION GAS PRESSURE MULTIPLIER
EP3049718A4 (en) Light with expanding compression member
TWD168204S (zh) 車頭燈（一）
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
EP3551913A4 (en) MULTI-PIECE STATOR ASSEMBLY HIGH PRESSURE VALVE
IL244043B (en) Anti - csf- 1r antibodies and uses thereof.
CA153896S (en) Injector
TWD165139S (zh) 項鍊
UA113482C2 (xx) Представлення багатоканального звуку з використанням інтерпольованих матриць
PL2943820T3 (pl) Matryca soczewek i sposób wytwarzania matrycy soczewek
EP3717997A4 (en) ESTIMATE OF CARDINALITY IN DATABASES
TWD166713S (zh) 用於基板托盤的封接件
AR097668A1 (es) Colorante-polímero
CA151655S (en) Applicator
EP3559519A4 (en) CALIBRATED MULTI-PRESSURE VALVE ASSEMBLY
TWD182471S (zh) 專用車輛
EP3724030A4 (en) BACKLIT THREE-DIMENSIONAL LAMP